<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<meta name="Generator" content="SAS Software Version 9.4, see www.sas.com">
<meta http-equiv="Content-type" content="text/html; charset=utf-8">
<title>SAS Output</title>
<style type="text/css">
<!--
.accessiblecaption
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.aftercaption
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.batch
{
  background-color: #FFFFFF;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 1px;
  color: #003399;
  font-family: 'SAS Monospace', 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  padding: 7px;
}
.beforecaption
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.body
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  margin-left: 8px;
  margin-right: 8px;
}
.bodydate
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  text-align: right;
  vertical-align: top;
  width: 100%;
}
.bycontentfolder
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.byline
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.bylinecontainer
{
  background-color: #FFFFFF;
  border: 0px solid #000000;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.caption
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.cell
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.container
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.contentfolder
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.contentitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.contentproclabel
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.contentprocname
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.contents
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
  margin-left: 8px;
  margin-right: 8px;
}
.contentsdate
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.contenttitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.continued
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
  width: 100%;
}
.data
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.dataemphasis
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.dataemphasisfixed
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.dataempty
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.datafixed
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.datastrong
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.datastrongfixed
{
  background-color: #FFFFFF;
  color: #000000;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.date
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.document
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.errorbanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.errorcontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.errorcontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.extendedpage
{
  background-color: #FFFFFF;
  border: 1pt solid #000000;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
  text-align: center;
}
.fatalbanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.fatalcontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.fatalcontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.folderaction
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.footer
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.footeremphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.footeremphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.footerempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.footerfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.footerstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.footerstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.frame
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.graph
{
  background-color: #FFFFFF;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.header
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headeremphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.headeremphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.headerempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headerfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.headersandfooters
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headerstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.headerstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.index
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.indexaction
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.indexitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.indexprocname
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.indextitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.linecontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.list9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.listitem9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.note
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.notebanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.notecontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.notecontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.output
{
  background-color: #CCCCCC;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.pageno
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
  text-align: right;
  vertical-align: top;
}
.pages
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
  margin-left: 8px;
  margin-right: 8px;
}
.pagesdate
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.pagesitem
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: none;
  margin-left: 6pt;
}
.pagesproclabel
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.pagesprocname
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  list-style-type: decimal;
}
.pagestitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.paragraph
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.parskip
{
  background-color: #FFFFFF;
  border-spacing: 0px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.prepage
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.proctitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.proctitlefixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooter
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooteremphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowfooteremphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowfooterempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooterfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.rowfooterstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowfooterstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheader
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheaderemphasis
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowheaderemphasisfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: italic;
  font-weight: normal;
}
.rowheaderempty
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheaderfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.rowheaderstrong
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.rowheaderstrongfixed
{
  background-color: #6495ED;
  color: #FFFFFF;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: bold;
}
.systemfooter
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemfooter9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: italic;
  font-weight: bold;
}
.systemtitle
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle10
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle2
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle3
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle4
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle5
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle6
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle7
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle8
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systemtitle9
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: medium;
  font-style: normal;
  font-weight: bold;
}
.systitleandfootercontainer
{
  background-color: #FFFFFF;
  border: 0px solid #000000;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.table
{
  background-color: #CCCCCC;
  border: 1px solid #000000;
  border-collapse: separate;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.top_stacked_value
{
  padding-bottom: 1px;
  border: 0;
}
.middle_stacked_value
{
  padding-top: 1px;
  padding-bottom: 1px;
  border: 0;
}
.bottom_stacked_value
{
  padding-top: 1px;
  border: 0;
}
.titleandnotecontainer
{
  background-color: #FFFFFF;
  border: 0px solid #000000;
  border-spacing: 1px;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
  width: 100%;
}
.titlesandfooters
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.usertext
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.warnbanner
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.warncontent
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: Arial, Helvetica, sans-serif;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.warncontentfixed
{
  background-color: #FFFFFF;
  color: #003399;
  font-family: 'Courier New', Courier, monospace;
  font-size: x-small;
  font-style: normal;
  font-weight: normal;
}
.l {text-align: left }
.c {text-align: center }
.r {text-align: right }
.d {text-align: right }
.j {text-align: justify }
.t {vertical-align: top }
.m {vertical-align: middle }
.b {vertical-align: bottom }
TD, TH {vertical-align: top }
.stacked_cell{padding: 0 }
-->
</style>
<script language="javascript" type="text/javascript">
<!-- 
function startup(){

}
function shutdown(){

}

//-->
</script>

</head>
<body onload="startup()" onunload="shutdown()" class="body">

<script language="javascript" type="text/javascript">
<!-- 
var _info = navigator.userAgent
var _ie = (_info.indexOf("MSIE") > 0
          && _info.indexOf("Win") > 0
          && _info.indexOf("Windows 3.1") < 0);
var _ie64 = _info.indexOf("x64") > 0

//-->
</script>

<div class="branch">
<a name="IDX"></a>
<table class="systitleandfootercontainer" width="100%" cellspacing="1" cellpadding="1" rules="none" frame="void" border="0" summary="Page Layout">
<tr>
<td class="c systemtitle">Energy data set 2</td>
</tr>
</table><br>
<div>
<div align="center">
<table class="table" cellspacing="1" cellpadding="7" rules="none" frame="box" summary="Procedure Print: Data Set REF2.ENERGY_SORTED_2">
<colgroup>
<col>
<col>
<col>
</colgroup>
<thead>
<tr>
<th class="r header" scope="col">sub_ref_no</th>
<th class="l header" scope="col">Title</th>
<th class="l header" scope="col">Research_Gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td class="r data">1</td>
<td class="l data">A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes</td>
<td class="l data">(A) Treatment with dapagliflozin in fasting situation =&gt; increases AA&#39;s and decreases lipid species. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Bioinformatic procedures =&gt; metabolic pathways =&gt; protective of renal function for SGLT2i dapagliflozin. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXx (C) Overlap in gene expression between (1) Metabolites targeted by dapagliflozin. (2) Intra-renal transcripts assoc. DKD =&gt; upregulation of pathway of BCAA corresponding BCAA&#39;s not changed. (3) Urea + urea cycle metabolites increased. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Increased levels of short chain acyl-carnitines reduced levels of myristoylcarnitine (long chain acyl-carnitines). XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) FAO incomplete surplus acyl-groups exported from mitochondria as acylcarnitines. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Reduced levels of acylcarnitines =&gt; larger degree of complete FAO. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Long chain acylcarnitines =&gt; fasting =&gt; increased short chain acylcarnitines. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) 3-Hydroxy FA reduces by dapagliflozin + high levels 3-OH FA&#39;s =&gt; markers of FAO disorders. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Improved FAO + increased fasting response, surplus 2- and 4-chain carbons. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Obese non-diabetic mice + canagliflozin =&gt; activation of catabolic pathways =&gt; FAO + mTOR inhibition + activation of AMPK. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Dapagliflozin =&gt; increased TCA cycle activity =&gt; increased expression of several TCA enzymes =&gt; eGFR =&gt; +ve effect on renal mitochondrial function. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) DKD =&gt; increased levels of metabolites + intermediates of TCA cycle + endoplasmic reticulum stress. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Cause of reduced TCA-cycle intermediates not clear explained by; (1) Improved mitochondrial efficacy. (2) Larger degree of complete FAO + increased gluconeogenesis (liver + kidney) =&gt; to compensate for urinary glucose loss. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Kynurenine redn =&gt; increased activity =&gt; picolinic acid increased + NAD+ further support improved mitochondrial function after dapagliflozin treatment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Long term protective effects of SGLT2i&#39;s on kidney =&gt; amelioration of mitochondrial function. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) SGLT2i =&gt; improves endothelial function + prevents accelerated renal function decline mechn =&gt; increased glycaemic control, metabolic control, osmotic duiresis + natriuresis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (Q) Dapagliflozin targeted pathways assoc. with DKD, molecular processes related to (1) energy metabolism (2) mitochondrial function (3) endothelial function. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Dapagliflozin slows progression of DKD. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Future research =&gt; refer to point (p). XXXXXXXXXXXXXXXXXXXXXXXXXXXX     XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) The exact mechanism of how SGLT2 inhibition improves endothelial function is not fully understood but may involve improved glycaemic and metabolic control, osmotic diuresis, and changes in sodium homeostasis as a result of increased natriuresis.</td>
</tr>
<tr>
<td class="r data">2</td>
<td class="l data">Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent cardiovascular disease</td>
<td class="l data">(A) 7000 participants + 3 prospective popn-based cohorts =&gt; present metabolic signature of atherosclerosis offering  insights =&gt; sytemic disturbances underlying atherosclerosis. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Atherosclerosis =&gt; associated with disturbances of interconnected pathways related =&gt; lipid, FA + CHO metabolism BCAA + AAA metabolism, TCA + urea cycle + muscle metabolism =&gt; largely consistent pattern between coronary + carotid atherosclerosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Metabolites above associated with =&gt; incident CVD events =&gt; highlighting the importance of these pathways =&gt; progression to clinical CVD. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Majority of these associations =&gt; attenuated substantially after adjustment for  conventional CVD risk factors =&gt; suggesting =&gt; metabolites lie on pathways closely associated with CVD risk factors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Beyond KEGG pathways =&gt; replicated metabolites highlight oxidative stress + inflammatory pathways. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) 5-oxoproline + glutamate =&gt; inversely associated CAC (chronic aortic calcification) + IMT (inter-medial thickness) =&gt; involved =&gt; synthesis + degradation glutathione. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Glutathione deficiency =&gt; oxidative stress =&gt; key role in pathogenesis of atherosclerosis. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) N-acetylneuraminic acid =&gt; +vely associated with CAC + IMT =&gt; major form of salic acid in mammals =&gt; biomarker sustained inflammatory response =&gt; subsequent effects =&gt; atherosclerosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Glycoprotein acetyls have previously shown =&gt; associations with risk of MI + stroke =&gt; consistent with CAC + IMT. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Lactate =&gt; +vely associated with IMT formed from pyruvate under insufficient O2 supply (hypoxia) =&gt; indicator of inflammation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Local hypoxia =&gt; occurs in highly active inflammed tissues =&gt; demands of increased cellularity exceed O2 supply =&gt; feature of atherosclerotic plaque. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Hypoxia =&gt; stimulate proatherosclerotic processes =&gt; including =&gt; deficinet lipid efflux, inflammation, interference with macrophage polarization + glucose metabolism. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) 4 metabolites =&gt; sugar + CHO metabolism =&gt; (D-glucose, 1,5-anhydrosorbitol, D-mannose + myo-inositol) =&gt; directly associated =&gt; CAC +/- IMT post adjustment for CVD risk factors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) 1,5-anhydrosorbitol =&gt; marker of glycaemic control =&gt; previously associated with CVD + kidney disease + close association =&gt; atherosclerotic disease, diabetes + IR. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Mannose =&gt; repeatedly associated =&gt; prediabetes, incident T2D + all cause mortality =&gt; in this study =&gt; highlight associated =&gt; atherosclerosis + incident CVD =&gt; independent of glucose. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Mannose =&gt; stronger correlations =&gt; lipids + N-acetylglycoproteins vs glucose. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Mannose =&gt; central role in glycation processes of lipoproteins =&gt; may initiate development of atherogenesis. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) N-glycans =&gt; upregulated in proinflammatory settings =&gt; found on cell surface =&gt; early stages of atherosclerotic plaque development. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Data =&gt; mannose could also affect CVD risk =&gt; through non-glucose dependent pathways. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Energy metabolism, TCA cycle + glycolysis =&gt; central pathways associated with atherosclerosis. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Alanine =&gt; synthesized directly from pyruvate, a product of glycolysis =&gt; supply cells with energy through TCA cycle =&gt; aerobic conditions. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Increase glucose utilization =&gt; in high risk atherosclerotic plaques. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Citrate =&gt; intermediate + key energy metabolite in the TCA cycle =&gt; previously associated with CV mortality. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Reduced O2 levels in the presence of atherosclerosis =&gt; affect TCA cycle which is O2 dependent. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Creatine, an amino acid derivative =&gt; reflects changes of energy metabolism in the muscles =&gt; transported through the circulation =&gt; taken up by tissues with high energy demands =&gt; with creatinine as the degradation product. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Creatinine levels =&gt; inversely associated with fat intake in animal studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Lipoprotein profiles analyses =&gt; confirmed association of these lipids with subclinical atherosclerosis, MI + stroke. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Further show =&gt; consistent picture between coronary + carotid atherosclerosis + CV events. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Association of TG&#39;s + atherosclerotic disease + future events was +ve even within HDL particles =&gt; supports previous observations. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Conversely not all HDL cholesterol was inversely associated with atherosclerosis highlighting the fact that causal association of HDL with lower CVD risk may be limited to certain particles (i.e. NOT the ones containing TG&#39;s). XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) In contrast =&gt; LDL + VLDL =&gt; consistently +vely associated =&gt; higher CAC + IMT + higher risk of CVD events + small trend =&gt; strong associations with decreasing density of lipoproteins. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Molecular interaction gene network map =&gt; interconnections between inflammatory, insulin + lipid pathways =&gt; metabolite markers of atherosclerosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Fibronectin 1 (FN1) =&gt; involved in cell adhesion + migration processes, including wound healing, blood coagulation + host defence; genetic polymorphisms within this gene =&gt; associated with =&gt; adverse lipid levels + CHD. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) CCAAT / enhancer-binding protein beta =&gt; master regulator of immunity + inflammation =&gt; other immunity related genes =&gt; (e.g. P13K complex) + pathways related to betaine-homocysteine metabolism (BHMT), glycolysis (pyruvate kinase) + angiogenesis (ANGPT4). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Summary =&gt; strong associations between serum metabolites =&gt; observed on 1H NMR spectroscopy + subclinical atherosclerosis =&gt; largely consistent between to vascular beds (coronary + carotid arteries). XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J1) Metabolic + gene networks =&gt; highly interconnected system  level metabolic disturbances =&gt; atherosclerosis =&gt; overlaps with the known CV risk factors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K1) Genetic approaches as well as mechanistic studies are now needed to further validate our results and to follow-up the possible entry points for investigation of novel targets or preventive strategies for atherosclerotic disease. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">3</td>
<td class="l data">Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With TypeÂ 2 Diabetes and Kidney Disease</td>
<td class="l data">(A) Profiling of acylcarnitines =&gt; incomplete FAO + increased catabolism of AA&#39;s =&gt; T2D + kidney disease. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Redn in plasma phosphatidylcholine levels + elevation of long-chain sphingomyelin + ceramide levels =&gt; remodelling of sphingolipids in T2D with DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C)Impaired renal filtration function + albuminuria levels =&gt; different metabolite signatures. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Targeted metabolomics =&gt; excellent survey of energy-yield pathways + fuel substrate selection. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Incomplete FAO =&gt; increased B-oxidn-derived even-number acylcarnitines. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Acceleration in catabolism of AA&#39;s esp. AAA&#39;s =&gt; DKD. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Increased levels of AA-derived acylcarnitines  + redn plasma levels of tyrosine + tryptophan =&gt; DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Excess intracellular + circulating acylcarnitines =&gt; excerbate metabolic disturbance =&gt; cytotoxicity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Accumulation of FAO + AA-derived metabolic intermediates in plasma =&gt; progression of DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Elevation of cluster of dicarboxyl + hydroxyl-carnitines in plasma =&gt; DKD XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Increased formation of dicarboxyl + hydroxyl dicarboxylic acids u-FAO + u-1 FAO =&gt; corresponding acylcarnitines =&gt; acyl-Co-A accumulation in DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) u-Oxidn =&gt; rescue pathway =&gt; mitochondrial FAO is impaired. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Endoplasmic retuculum stress =&gt; increased short chain diacid levels =&gt; accumulation =&gt; short + long-chain dicarboxylcarnitines =&gt; indicate mitochondrial stress and / or endoplasmic reticulum stress =&gt; activation of alternative FAO pathways =&gt; DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Accumulation of acetyl-Co-A-derived C2 (acetyl-carnitine) =&gt; mismatch =&gt; energy substrate flux or utilization in DKD. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Unable to ascertain whether imbalance =&gt; accelerated flux or redn in downstream utilization or BOTH. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Mitochrondrial function is impaired in DKD, redn electron transport chain (ETC) activaties + overall redn mitochondrial content + PGC-1a expression =&gt; DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Similar defects =&gt; diabetic islet, heart + skeletal muscle. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Impaired mitochondrial function partially explained by substrate flux / oxidn imbalance in DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) IR + other related metabolic disturbance in DKD =&gt; impair mitochondria + restrict its ability to select glucose =&gt; preferred substrate for oxidn (metabolic inflexibility). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Fuel supply + oxidn may not necessarily be reduced in presence of mitochondrial dysfunction. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Frank mitochondrial dysfunction (myopathies with impaired ETC activity) =&gt; increase fuel flux + oxidn =&gt; compensate for impaired ATP synthesis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Impaired mitochondrial function + energy substrate oversupply in T2D =&gt; intra-mitochonrial metabolic intermediates accumulation + extracellular overflow =&gt; circulation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Future in-vivo tracing study =&gt; isotope-labelled substrate =&gt; insights into substrate flux, selection + oxidization in DKD. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Long-chain sphingomyelin + ceramides increased in DKD sphingomyelin-ceramide pathway =&gt; renal complications. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Pathological mechns =&gt; mitochondrial impairment + increased generation of ROS, activation of apoptotic pathway, increased inflammatory tone + endoplasmic reticulum stress + contribute to overprodn short-chain diacids + long-chain dicarboxylacylcarnitine in DKD. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Redn phosphatidyl-choline + increment in sphingomyelin levels =&gt; sphingolipid remodelling in DKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX phosphatidyl-choline =&gt; choline phosphotransferase =&gt; sphingomyelin. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Renal filtration function + albuminuria levels =&gt; eGFR + ACR (albumin / creatinine ratio) =&gt; independent of predictors of CKD progression + genetic studies no overlap loci of eGFR + ACR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Assoc sphingomyelin + albuminuria =&gt; T2D. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Sphingomyelin =&gt; inhibition =&gt; ceramide (redn albumin excretion, protection of kidney function) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Sphingomyelin =&gt; ceramide metabolism =&gt; independently assoc. with albuminuria BUT not renal filtration in T2D. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Previous studies polymorphism of ceramide synthase 2 (CerS2) =&gt; changes in albuminuria BUT NOT eGFR in T2D. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (E1) Increased albumuria redn eGFR complimentary + overlapping =&gt; kidney damage. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Inverse assoc acylcarnitine levels + eGFR =&gt; non diabetic popns. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Acylcarnitine sub-species differed in non-DKD + DKD, short-chain diacids + AA-derived acylcarnitines =&gt; strong / independent association with eGFR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Altered energy substrate selection XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Imbalance of substrate flux + utilization. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J1) Remodelling of sphingolipids in T2D + DKD XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K1) Distinct metabolite signatures eGFR + albuminuria =&gt; different pathophysiological process underlying eGFR + albuminuria DKD in T2D.</td>
</tr>
<tr>
<td class="r data">4</td>
<td class="l data">Obesity and inflammation: the linking mechanism and the complications</td>
<td class="l data">(A) Sustained inflammation is considered a strong risk factor =&gt; developing many diseases =&gt; CVD&#39;s, metabolic syndrome, diabetes + cancer. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Obesity =&gt; predisposes to a pro-inflammatory state =&gt; via increased inflammatory mediators =&gt; IL-6 and TNF-a + redn levels of adiponectin (which has anti-inflammatory function). XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) TNF-a =&gt; overexpressed in overweight state + IL-6 =&gt; linked more to the obese state =&gt; influences =&gt; liver to synthesize + secrete CRP =&gt; feature of systemic inflammation. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Inflammatory state =&gt; reduced levels of adiponectin, =&gt; important implications on =&gt;  insulin sensitivity, reducing metabolic abnormalities + adjusting energy expediture. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Inflammatory state =&gt; vascular + endothelial dysfunction =&gt; characterized by decreased nitric oxide (NO) + elevated reactive oxygen species (ROS) =&gt; oxidative stress. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Both oxidative stress + inflammatory states =&gt; atherosclerosis, hypertension, alteration of metabolic markers =&gt; major adverse cardiovascular events. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">5</td>
<td class="l data">Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study</td>
<td class="l data">(A) Applying a MS-based acylcarnitine profiling platform =&gt; panel of acylcarnitines =&gt; esp. assoc. future risk of T2D =&gt; substantially improved predictive ability for incident T2D beyond conventional risk, inc BMI + fasting glucose. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Previous studies =&gt; obese + diabetic animal models =&gt; links of acylcarnitines =&gt; mild FAO dysregulation + mitochondrial stress =&gt; worsened IR + glucose deterioration. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Treating myotube + acylcarnitine =&gt; Akt phosphorylation + glucose uptake in response to insulin stimulation. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Redn of mitochondrial FA import or acylcarnitine synthesis =&gt; alleviate lipid-induced IR =&gt; lipid-induced  =&gt; mitochonrial stress =&gt; predates the emergence of glucose deterioration + diabetes. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Previous studies =&gt; acylcarnitine profiles, associated with insulin sensitivity, plus sig. different acylcarnitine profiles =&gt; normal glucose tolerance (NGT), prediabetic (impared glucose tolerance (IGT) +/- impaired fasting glucose (IFG)) + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Several prospective studies =&gt; medium and / or long-chain acylcarnitines =&gt; predicted cardiovascular events or mortality in &gt; 85 years or selected patients undergoing cardiac catheterization or dialysis. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) European studies targeted BIOCRATES metabolomics platform =&gt; no sig. assoc acylcarnitines + incident T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Differences in =&gt; study design methodology + statistical analyses + ethnic differences + lifestyle =&gt; explain discrepancy between our study + others. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Current study =&gt; selected acylcarnitines added to predictive models =&gt; substantially improved predictive ability =&gt; T2D beyond conventional risk factors e.g. BMI + fasting glucose (AUCs: 0.89 vs 0.73). XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Simple alternative approach =&gt; assess mitochondrial FAO dysregulation in vivo =&gt; specific acylcarnitine patterns =&gt; promising early biomarkers =&gt; T2D =&gt; long chain acylcarnitines =&gt; increased incident T2D. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Long chain FA&#39;s =&gt; oxidized predominately inside mitochondrion. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) LCFA&#39;s =&gt; transported across the mitochondrion inner membrane as long-chain acylcarnitine. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Initial metabolites of B-oxidn =&gt; accumulation of long chain acylcarnitine =&gt; reflect severe conditions of FAO dysregulation + mitochondrial overload + impaired tricarboxylic acid (TCA) cycle. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Obese + T2D subjects =&gt; increased non-esterified + long-chain acylcarnitines vs non-case subjects. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Underlying mechn unclear =&gt; in-vitro studies =&gt; treatment with long chain acylcarnitines =&gt; induced IR + oxidative stress in human myotubes + regulated calcium efflux in cardiac tissue + Human Ether-a-go-go-Related Gene (hERG) channels in renal cells. Potential functional roles =&gt; LCFA derivative =&gt; beyond biomarkers of mitochondrial dysfunction. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (P) The associations of medium-chain acylcarnitines + T2D remain uncertain, explanations could include, different precursors or metabolic compartments that are involved =&gt; generation of medium-chain acylcarnitines which could be later B-oxidn metabolites of LCFA or directly esterified derivatives from MCFA. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) MCFA&#39;s =&gt; pro-inflammatory agents in some studies in-vitro, BUT antimicrobial, anti-inflammatory agents in other studies in-vivo + in-vitro. MCFA&#39;s in metabolic disorders =&gt; remains to be elucidated. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Increased circulating 3-dehydroxycarnitine + 3-dehydrocarnitine =&gt; precursors of L-carnitine prodns =&gt; assoc lower risk incident T2D. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Previously, carnitine, improves insulin-stimulated glucose utilization + T2D-related metabolic disorders =&gt; humans + rodents. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Mechn =&gt; unclear =&gt; admin of 3-dehydroxycarnitine =&gt; mouse model lacking L-carnitine transporter =&gt; improved FA metabolism =&gt; potential benefits =&gt; carnitine precursors =&gt; maintaining energy homeostasis. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Findings =&gt; dicarboxylic acid acylcarnitines with odd chains or even chains =&gt; different impacts on the development of T2D. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Malonylcarnitine (C3DC) =&gt; indicator =&gt; reflect malonyl-CoA levels. Malonyl-Co-A =&gt; key regulators =&gt; mammalian energy homeostasis =&gt; inhibiting mitochondrial CPT1 + FAO. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) IR-patients with obesity + T2D =&gt; high muscle malonyl-Co-A concns. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Remains unclear whether malonyl-CoA accumulation =&gt; indicated by accumulated C3DC =&gt; serves as a feedback signal =&gt; suppress B-oxidn + mitochondrial stress =&gt; blocking CPT1 activity =&gt; to counteract lipid-induced IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) +ve C3DC-diabetes assoc. in our study =&gt; role of malonyl-CoA =&gt; diabetes pathogenesis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Unlike odd-chain dicarboxylic acids, even chain dicarboxylic acids =&gt; derived from v-oxidn of FA&#39;s thereafter =&gt; B-oxidn. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Intervention studies =&gt; sebacic acid (C10DC FA) + dodecanedioic acid (C12DC FA) =&gt; favourable impacts on glycaemic control + energy utilization =&gt; T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Inverse assoc. of C10DC + C12DC acylcarnitines =&gt; incident T2D =&gt; supported potential benefits of sebacic acid + dodecanoic acid in T2D. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Elastic net model =&gt; successful =&gt; predictive accuracy + sparsity =&gt; high-dimensional data sets =&gt; used in variable selection + model selection.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Acylcarnitines =&gt; sig. improved predicting power of T2D vs conventional risk factors =&gt; potential utility =&gt; novel early predictors of T2D risk assessment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) These findings need to be replicated in other populations, and underlying biological mechanisms should be elucidated in future studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">6</td>
<td class="l data">Adiponectin levels predict prediabetes risk: the Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study</td>
<td class="l data">(A) Biracial cohort =&gt; healthy offspring of patients with T2D =&gt; inverse association =&gt; adiponectinaemia (normal levels) =&gt; risk of incident prediabetes / diabetes =&gt; during longitudinal FU. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Initially normoglycaemic persons =&gt; increase 5ug/dl higher baseline plasma adiponectin level =&gt; 40% lower rate of progression =&gt; prediabetes / diabetes, 2.6 years of FU. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) 110 participants =&gt; end point (prediabetes) =&gt; 10 participants =&gt; progressed T2D (100 participants =&gt; prediabetes). XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Well-known ethnic + geneder differences in plasma adiponectin levels =&gt; present study. Association of adiponectin status + incident prediabetes =&gt; consistent across gender + ethnicity =&gt; African-Americans (AA) + European-Americans (EA). =&gt; parental history T2D. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Point estimates =&gt; reduced risk for prediabetes =&gt; same order of magnitude in black + white offspring (0.44 + 0.48 respectively) =&gt; 95% CI wider in whites. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Adjustment for BMI =&gt; increases adiponectin-associated OR =&gt; prediabetes from 0.48 =&gt; 0.61 + wider 95% Cl. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Observation =&gt; nominal redn = 40% in risk of incident prediabetes =&gt; despite adjustment for BMI =&gt; redn prediabetes risk assoc. with higher baseline adiponectin levels =&gt; partly mediated =&gt; adiposity related mechns. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Previous cross-sectional + longitudinal studies =&gt; low adiponectin levels =&gt; increased risk of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Prospective Diabetes Prevention Programme (DPP) =&gt; patients with prediabetes =&gt; increased 3ug/ml baseline adiponectin levels =&gt; predicted 20-40% lower risk  =&gt; T2D in 3 year FU. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Approx 5ug/ml (1SD) higher baseline adiponectin levels =&gt; 40%lower risk of progression from normoglycaemia =&gt; prediabetes. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Association of adiponectin with diabetes risk =&gt; evident of earlier stage in the pathogenesis of dysglycaemia. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Ability =&gt; maintain high adiponectin prodn =&gt; protective of dysglycaemia in high risk of T2D. Hypoadiponectinaemia =&gt; risk factor  =&gt; initiation of early glucose abnormalities =&gt; predibetes / diabetes. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Favourable cardiometabolic profile of adiponectin =&gt; emerged since discovery.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N)  Mechns =&gt; not fully understood how adiponectin exerts it&#39;s favourable cardiometabolic effects. BUT could involve =&gt; improvement of insulin action, redn inflammatory tone, interaction with fibroblast growth factor (FGF)-21 + amelioration of lipotoxicity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Rodent models =&gt; overexpression of adiponectin =&gt; several beneficial effects =&gt; increased metabolic flexibility, redn in inflammatory markers, redn steatosis, improved insulin sensitivity, redn apoptosis + preservation of B-cell function. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Interaction between adiponectin + FGF21, a potent regulator of metabolism + energy utilization. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) FGF-21 =&gt; redn blood glucose levels + increased insulin sensitivity in mouse models of obesity + IR =&gt; upregulation of adiponectin expression. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) FGF-21 =&gt; clearance of toxic ceramides in obese animals + adiponectin-knockout mice =&gt; refractory to ceramide-lowering effects of FGF-21. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Adiponectin =&gt; critical mediator =&gt; favourable metabolic + insulin sensitizing effects FGF21. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Improvement in insulin sensitivity with PPAR-y agonists =&gt; mediated, in part =&gt; upregulation of adiponectin expression. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Intervention that increased adiponectin levels =&gt; attractive candidates =&gt; clinical trials =&gt; diabetes prevention + improvement =&gt; cardiometabolic health. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Interactions =&gt; increased adiponectin levels =&gt; exercise, weight loss, smoking cessation + treatment with PPAR-y agonists, PPAR-a agonists, ACE inhibitors + angiotensin 2 receptor blockers. All these interventions =&gt; favourable glucoregulatory outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Prediabetic participants =&gt; lifestyle intervention arm in DPP =&gt; increased circ adiponectin levels =&gt; 58% relative risk redn in incident diabetes vs placebo group. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Cross-sectional + longitudinal studies =&gt; low adiponectin levels =&gt; prevalent T2D, impaired glucose homeostasis =&gt; unfavourable cardiometabolic profile. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) AA&#39;s + EA&#39;s =&gt; parental history of T2D =&gt; enrolled in POP-ABC study, baseline adiponectin levels =&gt; inversely related =&gt; risk of incidient prediabetes.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Predictive relationship evident =&gt; despite gender + ethnic differences in baseline adiponectin levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Interventions =&gt; increased adiponectin levels =&gt; protection against the risk of dysglycaemia regardless of gender or ethnicity. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) The mechanisms whereby adiponectin exerts its favorable cardiometabolic effects are not fully understood, but could involve improvement in insulin action, decreased inflammatory tone, interaction with fibroblast growth factor (FGF)-21 and amelioration of lipotoxicity, among others. (34â39) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">7</td>
<td class="l data">Biomarkers of rapid chronic kidney disease progression in type 2 diabetes</td>
<td class="l data">(A) T2D + CKD3 =&gt; large set of candidate and global discovery biomarkers =&gt; at least 62 =&gt; evidence of association with rapid renal function decline. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Many biomarkers =&gt; high correlations with each other  + clinical covariates =&gt; a much sparser set of 14 biomarkers =&gt; contained the most predictive information beyond clinical covariates. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX X (C) These biomarkers =&gt;  incremental prediction that was sufficient in magnitude =&gt; provide risk stratification into clinical trials. Some biomarkers are already known to be associated with eGFR (B2-microglobulin + cystatin-C). Others are unknown biomarkers associated with eGFR (SDMA (symmetric dimethylarginine) / ADMA (Asymmetric dimethylarginine) ratio, FGF-21 + uracil). XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (D) The best biomarker predictive panel =&gt; restricted clinical covariates + 35 biomarkers, BUT only modestly better than the best sparse model =&gt; 14 biomarkers =&gt; expense + logistics favoured the 14 biomarker (sparse) model vs best biomarker predictor model (clinical covariates + 35 biomarkers). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX    (E) Used clinical creatinine measurements to calculate eGFR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Focused the study on more novel biomarker associations. Strongest biomarker associations =&gt; released during proteolytic breakdown of nuclear proteins =&gt; studied as biomarkers for CVD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (G) SDMA =&gt; excreted via the kidney =&gt; strongly associated with renal function, BUT =&gt; protein methyl-transferase (PRMT5) =&gt; synthesizes SDMA =&gt; ALSO regulates interleukin-2-gene expression =&gt; higher SDMA levels =&gt; may reflect inflammation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (H) No asssociation of SDMA =&gt; C-reactive protein inflammatory biomarker, BUT +ve correlation (r=0.39) with interleukin-2 receptor a levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Study finding =&gt; SDMA accumulates when kidney filtration falls =&gt; good biomarker of filtration. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) In contrast to SDMA =&gt; ADMA =&gt; weakly inversely correlated =&gt; eGFR, BUT strongly correlated =&gt; arginine. The SDMA / ADMA ratio =&gt; biomarker of these complex interactions. SDMA / ADMA =&gt; had higher predictive power (AUROC) vs SDMA or ADMA separately. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (K) KIM-1 =&gt; protein expressed on apical membrane =&gt; proximal tubule cells =&gt; ectodomain =&gt; shed into the lumen =&gt; serves as a urinary biomarker of kidney injury =&gt; mixed results =&gt; prognostic biomarker =&gt; diabetic kidney disease. KIM-1 expression increased =&gt; glomerulus of diabetic animal models + elevated plasma levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Shed KIM-1 =&gt; serves as a blood biomarker in kidney injury in humans =&gt; plasma KIM-1 levels higher in patients with acute kidney injury (AKI) vs healthy controls or post-cardiac surgery patients without AKI. A study serum KIM-1 level at baseline =&gt; T1D =&gt; strongly predicted rate of eGFR loss + risk of ESRD =&gt; 5 - 15 years of FU. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (M) Associations =&gt; rapid progression of two fibroblast growth factors =&gt; FGF-21 + FGF-23. FGF-21 =&gt; 181 AA polypeptide =&gt; secreted in liver + adipose tissue =&gt; role in lipid + energy metabolism. Previous studies cross-sectional association with eGFR. Median serum FGF-21 levels =&gt; &gt; 7-15-fold higher in dialysis patients vs controls, BUT fell after short term angiotensin blockade. Crossectional associations =&gt; FGF-21 levels elevated =&gt; albuminuria when eGFR &gt;60ml/min. FGF-21 =&gt; independently associated =&gt; urinary albumin in T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Kidney =&gt; relatively low levels of FGF-21 =&gt; FGF-21 activity =&gt; depends on tissue specific expression =&gt; cofactor Klotho B =&gt; predominantly in liver + adipose tissue vs kidney. Association of FGF-21 + renal disease progression =&gt; simple accumulation in renal disease. However =&gt; may reflect =&gt; antifibrotic response =&gt; FGF-21 =&gt; prevented expression of profibrotic cytokines =&gt; transforming growth factor-B1 in the kidney. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) FGF-23 =&gt; 32-kD bone-derived hormone =&gt; several known endocrine functions in the kidney + promotion of urinary phosphate excretion + inhibition =&gt; hydroxylation =&gt; 25-hydroxyvitamin D. Elevated FGF-23 =&gt; independent risk factor for ESRD =&gt; in patients with perserved kidney function + mortality across a spectrum of CKD. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Atheroscelerosis Risk in Communities study (ARIC) =&gt; higher serum level FGF-23  =&gt; increased risk =&gt; incident ESRD, independent of baseline level of kidney function + other risk factors. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (Q) C 16-acylcarnitine =&gt; strongest predictors =&gt; rapid progression. KORA study =&gt; acylcarnitine =&gt; ratio of serine to glutarylcarnitine =&gt; associated with eGFR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) However, further studies of the generalizability of findings are warranted. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Validation in external cohorts is needed. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) It is not possible to conclude that biomarkers that are associated with progression at this stage will also be predictive of progression in individuals with CKD1 or CKD2 and studies are needed to examine biomarkers in such individuals. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Identified novel associations of biomarkers that warrant further investigation for relevance to pathogenesis of kidney disease in type 2 diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">8</td>
<td class="l data">Dietary diabetes risk reduction score, race and ethnicity, and risk of type 2 diabetes in women</td>
<td class="l data">(A) Cohorts of women =&gt; observed =&gt; higher dietary diabetes risk redn score =&gt; inversely associated with risk of T2D in women of all individual racial + ethnic groups + overall minority women. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Relative risk estimates =&gt; similar across racial + ethnic groups =&gt; absolute risk difference =&gt; same contrast in dietary score =&gt; large for the minority women vs NHW women. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Well established =&gt; use of healthier lifestyle =&gt; modification of diet =&gt; diabetes prevention BUT limited evidence these findings apply to racial / ethnic groups =&gt; at elevated risk of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Epidemiological analyses =&gt; evidence on racial + ethnic differences =&gt; relation of diet + risk of diabetes =&gt; inconsistent. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Findings =&gt; consistent with those observed by Qiao =&gt; examined racial / ethnic differences =&gt; association between dietary quality (measured by Alternate Healthy Eating Index (AHEI)) + risk of incident diabetes. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Higher dietary quality =&gt; predicted lower risk of diabetes =&gt; White + Hispanic women BUT not Black or Asian women. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Current study =&gt; observations were stronger =&gt; possibly due to updated dietary data + dietary score reflected more recent findings for diet + diabetes. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Significant inverse associations in all racial + ethnic minority groups vs Qiao =&gt; observed wide CI&#39;s prevented them from finding significant associations in all minority groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Our overall findings =&gt; consistent with those of previous observational studies =&gt; predominantly NHW women. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Few studies =&gt; compared associations =&gt; specific dietary factor =&gt; GI + cereal fibre + T2D =&gt; across different racial + ethnic groups. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Our study =&gt; higher GI + lower cereal fibre intake =&gt; associated with greater risk of T2D in minority women. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Results =&gt; consistent with a few studies of minority women, =&gt; another study =&gt; cereal fibre inversely associated with risk of T2D in Whites BUT role of GI + dietary fibre + diabetes in Blacks =&gt; unclear. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Previous prospective cohort studies =&gt; daily servings of sugar soda beverages (SSB) =&gt; associated with increased T2D risk in NHW + Black women. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) We found  =&gt; 25% higher risk of developing T2D =&gt; increase of one serving of SSB / day in NHW women + 16% higher risk in minority women. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Prior research =&gt; SSB&#39;s =&gt; generate low satiety + often consumed in addition to usual food intake =&gt; increased energy intake + ultimately weight gain. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Adjusted for BMI in a separate model =&gt; association remained +ve  + significant in NHW + minority women =&gt; suggesting =&gt; association of SSB&#39;s + T2D risk =&gt; cannot be entirely attributed to BMI. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (R) Potential harmful effects of SSB&#39;s on T2D risk =&gt; strong epidemiologic evidence =&gt; in contrast =&gt; protective association of coffee + risk of T2D risk. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Our study =&gt; 10% redn =&gt; risk of diabetes per one cup increase of coffee per day in NHW women + 12% redn in risk in overall minority women. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Dearth of evidence =&gt; racial + ethnic differences =&gt; association between red + processed meat intake + risk of T2D =&gt; one study =&gt; risks, similar in magnitude in Caucasian women + Japanese American women.  XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Current study =&gt; higher intake of red + processed meats =&gt; +vely associated with T2D risk =&gt; White (34% higher risk) + minority (14% higher risk) women. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) We found =&gt; significant +ve assocation =&gt; trans fat intake + risk of T2D in NHW women =&gt; BUT assocation not significant in minority women. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) P:S =&gt; not significantly associated =&gt; T2D risk in NHW or minority women. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Further studies =&gt; intakes of different types of fat + red + processed meats + T2D in different racial / ethnic popns =&gt; needed =&gt; to confirm =&gt; racial / ethnic differences in the association =&gt; dietary factors + T2D risk. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (y) One notable finding of this study =&gt; despite similar relative risk estimates across racial + ethnic groups =&gt; absolute risk difference for the same contrast in dietary score =&gt; larger for minority women vs White women. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Minorities =&gt; lower insulin sensitivity + insulin secretion capacity vs NHW&#39;s =&gt; could explain =&gt; higher prevalence of IR + increased risk of diabetes in minority popns. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Minority popns =&gt; higher absolute risk of T2D =&gt; benefit that can be confered =&gt; healthy diet =&gt; greater in these popns vs NHW women =&gt; our findings. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Expected mean differences in BMI =&gt; across racial / ethnic groups =&gt; ran  another analysis =&gt; using WC in a subset of participants (76%) =&gt; available anthropmetric data. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Magnitude of associations =&gt; did NOT change appreciably by adjusting for WC in place of BMI =&gt; BUT CI&#39;s widened BECAUSE of small sample size. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">9</td>
<td class="l data">Characteristics of glucose metabolism in Nordic and South Asian subjects with type 2 diabetes</td>
<td class="l data">(A) Ethnic differences in glucose + fat metabolism + energy expenditure =&gt; basal + clamp hyper-insulinaemic conditions =&gt; subjects with T2D =&gt; SA or NOR ethnicity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Ethnic differences =&gt; fasting endogenous glucose prodn + indications of possible differences =&gt; choice of substrates =&gt; energy expenditure =&gt; basal + clamp conditions. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Concept of ethnicity + ethnic groups =&gt; complex =&gt; socio-cultural + biological components =&gt; not clearly defined. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) South Asian ethnicity =&gt; diverse =&gt; several countries =&gt; differences in culture, religion + diet, BUT the term South Asian =&gt; justified =&gt; high prevalence of diabetes + increased IR present =&gt; whole region =&gt; esp. urban areas + migration to Western Countries. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Higher fasting (endogenous glucose prodn) EGP in SA vs NOR =&gt; not explained by examined confounding factors. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) During clamp hyperinsulinaemia =&gt; EGP redn + ethnic difference was attenuated, BUT EGP clamp was still not neglible =&gt; constituted 40% of (total glucose disposal) TGD in SA + 25% in NOR. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Hyperinsulinaemia during clamp =&gt; suppress EGP almost entirely + euglycaemic clamp studies =&gt; frequently performed without measurement of EGP BUT that EGP clamp persists. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Present further evidence =&gt; EGP clamp =&gt; substantial in T2D =&gt; even with serum insulin concns during clamp as high as 1000 - 1500 pM =&gt; underscores the importance of controlling for hepatic glucose prodn during clamp studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Finding predictors for estimation of EGP clamp =&gt; are variables that are easier to measure  =&gt; group of variables =&gt; correlated with EGP clamp =&gt; regression analysis =&gt; explained only 15% of EGP clamp variation. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Most of the variables correlated significantly with the NOR group. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Exogenous glucose infusion rate =&gt; no correlation with EGP clamp. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) SA group =&gt; only sig. correlation, between =&gt; EGP clamp + TGD =&gt; reflecting high percentageof EGP clamp in TGD in this group. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Suggests =&gt; measuring EGP clamp, + exogenous glucose infusion rate =&gt; essential =&gt; correct estimation of TGD rate. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Ethnic groups residing in tropical climates =&gt; previously shown =&gt; lower (resting energy expenditure) REE vs Westerners =&gt; need for adjusting REE for fat free mass (FFM) + fat mass (FM) + age + sex. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Lower REE in SA =&gt; shown to be due to differences in body composition =&gt; not ethnicity per se. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) The 2 ethnic groups =&gt; clear differences in body composition =&gt; adjusting for these differences =&gt; mostly FFM =&gt; attenuates ethnic differences in REE. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Complex concept + definition of ethnicity =&gt; lower FFM =&gt; ethnic characteristic of SA&#39;s XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Basal, resting conditions, energy prodn =&gt; derived from lipids + less from carbohydrates =&gt; our study =&gt; highly significant correlation between REE + fat oxidn in both ethnicities. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) SA group =&gt; near sig. correlation between REE + EGP-basal =&gt; could signify increased use of carbohydrates as energy substitute in the fasting state in SA to such an extent  =&gt; important for the total REE. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Do not find any ethnic differences =&gt; basal (respiratory quotient) RQ or in (change in respiratory quotient) DRQ from fasting to clamp hyper-insulinaemic conditions =&gt; this would have clearly indicated  =&gt; ethnic difference in metabolic flexibility. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Previous study =&gt; insulin stimulated RQ =&gt; dependent on glucose disposal rates =&gt; our study =&gt; similar in both groups. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) NOR subjects =&gt; sig. more obese vs SA =&gt; in part explain no obvious ethnic differences in TGD, after adjustments =&gt; differences in waist circumference + EGP =&gt; ethnic difference in TGD =&gt; closer to significant. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Our study =&gt; non-sig. trend =&gt; higher oxidative / non-oxidative glucose metabolism in SA vs NOR in the basal, post-absorptive state. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Total EGP basal sig. higher =&gt; higher degree of hepatic IR in SA. =&gt; speculation =&gt; possible higher basal oxidative glucose metabolism in muscle =&gt; triggered by increase substrate availability =&gt; fasting hyperglycaemia =&gt; less use of lipids as energy substrate  =&gt; lipid accumulation =&gt; further aggravation of hepatic insulin resistance =&gt; metabolic inflexibilty hypothesis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Post-absorptive conditions skeletal muscle contribution =&gt; total metabolism is modest =&gt; possible ethnic difference in muscle metabolism =&gt; masked. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Hepatic IR =&gt; caused by increased lipid storage in liver =&gt; due to adipose tissue overflow. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Percentage truncal fat =&gt; similar in our two ethnic groups =&gt; BUT NOR group significantly more obese. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Previous study =&gt; group of Pakistani + Norwegian subjects =&gt; T2D =&gt; similar abdominal adipose tissue distribution =&gt; visceral adipose tissue =&gt; more metabolically active =&gt; Pakistani subjects. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Increase supply of NEFA (non-esterified FA&#39;s) from visceral adipose tissue =&gt; liver =&gt; increased IR + substrate =&gt; gluconeogenesis. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (D1) Gluconeogenesis increased in T2D =&gt; largely responsible for increased post-absorptive EGP. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) Using glucose as a tracer =&gt; Cori cycling =&gt; included in estimation of TGD =&gt; increased 25% in T2D in general. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Non-oxidative glucose metabolism in SA =&gt; corresponds to Cori-cycling =&gt; due to =&gt; substrate availability through hyperglycaemia in tissues =&gt; lactic acid prodn in muscle or other tissues =&gt; anaerobic glycolysis =&gt; transport =&gt; liver  =&gt; re-use as substrate in gluconeogenesis =&gt; vicious circle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Data from this study =&gt; baseline results from vitamin D intervention trial =&gt; assocations of 25-hydroxyvitamin D levels + insulin sensitivity + insulin secretion. Significantly lower median 25-hydroxyvitamin D levels in SA group. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Could differences in vitamin D levels =&gt; explain =&gt; ethnic differences =&gt; glucose metabolism? XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Recent studies =&gt; shown  =&gt; relationship between Vitamin D + T2D, metabolic syndrome, IR + insulin secretion. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J1) Most published studies =&gt; sig. associations, effect of vitamin D intervention =&gt; primary end-point =&gt; surrogate markers =&gt; based on fasting blood values (HOMA indices). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K1) Sophisticated methods =&gt; OGTT, IVGTT or clamps =&gt; not been able to show sig. relations. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L1) Our study =&gt; no sig. assoc. levels of 25-hydroxyvitamin D + TGD or AIGg =&gt; Is there a genuine + casual relationship between vitamin D + T2D =&gt; await =&gt; RCT =&gt; results. XXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">10</td>
<td class="l data">Effect of uridine on energy metabolism, LPO, and antioxidant system in the myocardium under conditions of acute coronary insufficiency</td>
<td class="l data">(A) Occlusion of LCA (left coronary artery) for 60min =&gt; reduced ATP content in the rat heart by 35% vs intact animals. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) The content of another macroergic compounds (Phosphagens =&gt; macrogenic compounds =&gt; energy storage compounds =&gt; high energy phosphate compounds =&gt; found in muscle tissue). XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) The type of biomolecule used as a phosphogen is dependent on the organism. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Majority of animals =&gt; arginine as phosphagen BUT phyllum Chordata (animal with spinal cords) =&gt; use creatine. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Creatine phosphate (CP), or phosphocreatine (PCr) =&gt; made from ATP by enzyme creatine kinase reversible reaction. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Creatine + ATP &lt;=&gt; Creatinine kinase &lt;=&gt; Creatine phosphate + ADP + H+ XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Creatine phosphate also considerably decreased by 59%. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Deficiency of macroergic compounds in ischaemic myocardium =&gt; prounced accumulation of lipid peroxides (by 97%). XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Plus suppression of SOD activity (by 28%) + glutathione system =&gt; decrease content of reduced glutathione (by 30%). XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Respiratory Chain (electron transport chain (ETC)) =&gt; Electrons leak from ETC =&gt; 2 electrons + O2 + 4H+ ==&gt; 1 electron + 2H2O + O2 =&gt; Superoxide anion O2(-) + Superoxide anion O2(-) =&gt; superoxide dismutase (SOD) =&gt; O2 + Hydrogen Peroxide (H2O2) =&gt; glutathione peroxidase =&gt; H2O XXXXXXXXXXXXX GSH (reduced glutathione) =======================&gt; GSSG (oxidised glutathione). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX GSSG (oxidised glutathione) =================&gt; GSH (reduced glutathione) X  NADPH ==================================&gt; NADP+ XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX NADP+ ==================================&gt; NADPH XXXXXXXXXXXXXXXX Glucose-6-phosphate ====================&gt; glucose-6-phosphogluconate X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Reperfusion to restore the flow of oxygenated blood =&gt; ischaemic tissue =&gt; oxygen free radicals =&gt; reperfusion-induced injury. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Serum paraoxonase activity increased 93% =&gt; HDL-associated enzyme =&gt; anti-atherogenic + anti-oxidant properties =&gt; prevent lipid oxidn in HDL. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Admin =&gt; uridine 5min prior to LCA occlusion =&gt; limits changes of energy metabolism in ischaemic myocardium + preserved high content ATP + creatine phosphate. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Uridine =&gt; prevented overprodn =&gt; lipid hydroperoxides + inhibition (anti-oxidant system) AOS enzymes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) (5-hydroxydecanoate) 5-HD =&gt; admin 5 min before uridine injection + LCA occlusion =&gt; abolished the protective effect of this prepn. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Animals in this group =&gt; content of ATP + creatine phosphate =&gt; remained at control level. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Prevention =&gt; lipid hydroperoxide overprodn + AOS activation by uridine =&gt; abolished =&gt; blockade of mitoKATP channels. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Findings =&gt; energy stabilizing effect of uridine + capacity to prevent LPO intensification + AOS inhibition =&gt; related to activation of mitoKATP-channels. (S) 5 min after admin of the nucleoside (uridine) =&gt; intact rats =&gt; blood content increased 11-fold vs baseline value (65.3 +/- 3.6 vs 5.9 +/- 0.3 umol/l). XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Similar increased =&gt; animals receiving uridine injection before LCA occlusion. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Sharp increase in uridine concn =&gt; elimination. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Rate of uridine elimination in blood =&gt; similar in both animals with / without LCA occlusion =&gt; no difference in concn between two groups. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Uridine content =&gt; rats =&gt; AMI =&gt; 15min after IV injection =&gt; sharply decreased to 10.3 +/- 0.9umol/l =&gt; dropped below baseline =&gt; 30th min (4.9 +/- 0.5umol/l). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) 15min post uridine injection =&gt; blood uridine levels =&gt; 18.5 +/- 1.7umol/l (intact rats) 2-fold lower than in rats with AMI (p&lt;0.05). XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) 30th min post uridine injection =&gt; uridine redn to 12.4 +/- 0.8 umol/l. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Excessive concns of uridine in these animals (8.0 +/- 0.6 umol/l) persisted over 60 min. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Previously reported =&gt; considerable disturbances of energy metabolism in ischaemic myocardium =&gt; post 15min after LCA ligation + peaked post 30min. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Our findings =&gt; coincided with accelerated elimination of uridine from the circulation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Related to increased myocardial demands for uridine under hypoxic conditions =&gt; activation of intracellular defense + adaptation mechns, esp. during periods of pronounced energy metabolism disturbances. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Our experiments =&gt; uridine =&gt; increased myocardial resistance to O2 deficiency under conditions of AMI. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) In animals with MI =&gt; uridine =&gt; rapidly disappears from circulation =&gt; promotes anti-ischaemic cardiomyocyte defense mechns =&gt; stabilization of energy metabolism + maintenance of balance of LPO + AOS. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Experiments =&gt; selective mitoKATP channel blocker =&gt; 5HD =&gt; suggest =&gt; realization of protective effect of uridine =&gt; related to mitoKATP channel. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Current + previous studies =&gt; uridine promising cardioprotective prepn for prevention + therapy of AMI. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">11</td>
<td class="l data">Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41)</td>
<td class="l data">(A) High expression level of GPR41 in sympathetic ganglia =&gt; indicates that GPR41 might play an important role in these cells. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) A series of in vitro + in vivo studies with GPR41 -/- mice showed =&gt; that an SCFA propionate potently activates SNS at sympathetic ganglia XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) The mechn of GPR41-mediated activation of sympathetic ganglion neurons is not mediated by cAMP inhibition =&gt; but rather involves GBy + MAPK signalling. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Furthermore =&gt; the major ketone body B-Hydroxybutyrate =&gt; antagonizes SCFA-GPR41 signalling + thereby inhibits SNS. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) As SCFA&#39;s + ketone bodies reflect the nutrient conditions =&gt; these moncarboxylic metabolites =&gt; appear to control energy balance by directly regulating GPR41-mediated sympathetic activation. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) The GPR41-SNS activation pathway may work as one of the important physiological mechns for these metabolic fuels to regulate body balance, GPR41 had been reported to be expressed in adipose tissue in mice + humans + to stimulate leptin secretion. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Recent studies =&gt; however =&gt; reported GPR41 =&gt; not expressed in mouse adipose tissues. Our quantitative RT-PCR (qRT-PCR) analysis also found that GPR41 is not detected in mouse adipose tissues. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) In contrast to GPR41 =&gt; we found that GPR43 is highly expressed in mouse adipose tissues by qRT-PCR =&gt; confirming previous reports. Because propionate can activate GPR43 =&gt; it is possible that propionate can affect the SNS by GPR43-mediated effects on adipocytes =&gt; especially by secretion of leptin =&gt; potently activate the SNS. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) However =&gt; administration of propionate induced a similar extent of alterations in metabolic parameters + leptin levels in wild-type + GPR41 -/- mice =&gt; propionate =&gt; propionate-activated GPR43 responses in GPR41 -/- mice were similar to wild-type mice. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) The results further confirmed the previous reports that SCFA&#39;s =&gt; can promote leptin secretion from adipose + not via GPR41. Taken together =&gt; the results showed that the effects of SCFA&#39;s on SNS activity may not be mediated by their effects on adipocytes from which adipocytokines such as leptin that can change sympathetic nerve activity can be secreted. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) GPR41 is a Gi/o-coupled G protein-coupled receptor (GPCR) related to =&gt; inhibition of cAMP prodn. In general =&gt; Gi/o-coupled GPCRs  =&gt; work as inhibitory system. However =&gt; our study shows that activation of GPR41 by SCFA excites the SCG neurons by generating action potential =&gt; releases noradrenaline from sympathetic nerve terminals =&gt; showing that GPR41 mediates an excitatory signalling. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Recently =&gt; many excitatory responses in a variety of cell systems have been reported to be mediated via GBy but not via Ga(i/o). XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Our study =&gt; selective antagonists for Ga(i/o) and GBy also showed that =&gt; GPR41-mediated excitation of SCG neurons =&gt; mediated by GBy signalling but cAMP inhibition by Ga(i/o) is not. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Furthermore =&gt; our siRNA experiments showed that =&gt; GPR41-mediated activation of sympathetic neurons involves PLCB + MAPK signalling + because GBy signalling activates MAPK signalling via PLCB in Gi/o-coupled GPCRs =&gt; our results may indicate that GPR41-induced sympathetic activation involves GBy-PLCB-MAPK signalling. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Under fed conditions =&gt;  a substantial proportion of total dietary energy intake derives from SCFA&#39;s produced via the colonic fermentation of dietary fibres by gut microbiota (5-10%). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Levels of SCFA&#39;s in the GIT vary significantly =&gt; depending on the amount of non-digestable fibre in the diet + also relate to the composition of the gut microbiota. Change in the amount + composition of the gut microbiota =&gt; implicated in cardiovascular diseases + obesity in humans. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Ketogenic conditions =&gt; have been suggested as a reason for the increased incidence of cardiac disorders. Furthermore =&gt; SCFA&#39;s =&gt; profoundly affect inflammatory responses via the chemoattractant receptor GPR43. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  (Q) Because of the plethora of physiological processes are regulated by SNS, SCFA-GPR41 interactions that regulate SNS could represent a central mechanism to account for the effects of diet, prebiotic + probiotics on body homeostasis + may represent avenues for understanding + potentially manipulating physiology + disease.</td>
</tr>
<tr>
<td class="r data">12</td>
<td class="l data">Iron overload and diabetes risk: a shift from glucose to Fatty Acid oxidation and increased hepatic glucose production in a mouse model of hereditary hemochromatosis</td>
<td class="l data">(A) Increased tissue iron levels =&gt; associated with diabetes =&gt; human heretitory haemochromatosis (HH) + dietary iron overload. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) At least partially the result of decreased insulin secretion, tissue iron overload =&gt; significant changes in glucose metabolism in skeletal muscle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) The effect on iron is to increase glucose uptake =&gt; a change that would be predicted to be protective of diabetes. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) To better understand the changes in overall fuel economy caused by iron =&gt; diabetes =&gt; investigated =&gt; muscle + hepatic =&gt; CHO + FA metabolism =&gt; mouse model =&gt; targeted deletion of the gene most commonly mutated in human HH, Hfe. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Shown =&gt; Hfe -/- mice =&gt; shift in fuel preference from glucose =&gt; FA oxidn =&gt; in muscle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Decrease glucose oxidn in muscle =&gt; associated with =&gt; increased pyruvate / lactate recycling to liver =&gt; demonstrated by previous metabolic flux studies + increased hepatic glucose output (Cori cycling). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) These combined effects =&gt; increased prevalence of diabetes in individuals with HH. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Our results =&gt; consistent with the close coupling of metabolism =&gt; iron availability =&gt; demonstrated in lower eukaryotes. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Decreased glucose oxidn in skeletal muscle =&gt; partly due to decreased PDH activity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Mechn =&gt; likely =&gt; observed increase in PdK4 mRNA, PDK4 activity =&gt; regulated at the transcription level. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Candidate mediator for regulation of PdK4 =&gt; may be increased AMPK activity =&gt; previously reported =&gt; Hfe -/- mouse muscle. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Other factors contributing to decreased glucose oxidn =&gt; modest degree of mitochondrial dysfunction + increased FA oxidn. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Mitochondrial dysfunction in Hfe -/- muscle =&gt; relatively minor contributors =&gt; given the increased capacity for FA oxidn apparent in mice on high-fat diets. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Mechn =&gt; increased FA oxidn =&gt; increased AMPK activation + decreased ACC activity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Increase Cptb expression =&gt; may play a role + changes in malonyl-CoA (not assessed). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Related to current findings =&gt; mice overexpressing erythropoietin in muscle =&gt; exhibit a similar phenotype to iron-overloaded mice =&gt; increased FA oxidn, decreased glucose oxidn + protection from diet-induced obesity (iron levels not measured in this model). XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Iron sufficiency =&gt; facilitate unimpaired erthropoiesis =&gt; advantageous for iron-sufficient mouse to shift to the more energy-efficient BUT oxygen-inefficient fuel source of FA&#39;s to make use of that capacity for oxygen transport. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Under opposite condition of hypoxia =&gt; FA oxidn decrease, enzymes for fat metabolism downregulate + glucose oxidn increases. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) The adaptive relationship between iron + fuel choice, Hfe -/- mice =&gt; consume more oxygen + produce more heat when fat is available in the diet. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Decreased ability =&gt; transfer between utilization of CHO + lipid fuel sources =&gt; metabolic inflexibility =&gt; characteristic =&gt; metabolic syndrome + T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Data, most consistent =&gt; increased hepatic glucose prodn =&gt; increased recycling of lactate + pyruvate (previously documented by isotopmer analysis of the fate of 1, 2 [13C] glucose. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Increase in hepatic glucose prodn =&gt; mainly substrate driven =&gt; levels of mRNA for gluconeogenic enzymes =&gt; not increased + glucose prodn =&gt; exogenous pyruvate =&gt; not enhanced. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) Data =&gt; do not support changes in insulin signalling as the underlying cause of the phenotype. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) CONCLUSIONS =&gt; Diabetes risk engendered by iron operates not only through toxic effects on B cells mediated by increased oxidative stress + mitochondrial dysfunction. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Liver of Hfe -/- mice exhibits increased glucose output with patterns of hepatic gene regulation + metabolite levels suggesting that gluconeogenesis in largely substrate-driven + results from altered fuel choice in muscle. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) Findings =&gt; help elucidate the association between iron + diabetes =&gt; not only in haemochromatosis BUT not-haemochromatotic individuals with metabolic syndrome or T2D associated with dietary iron excess. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Chronically increased fat oxidation, especially in the setting of decreased mitochondrial function, might also contribute to the accumulation of lipid products that have been implicated in the pathogenesis of diabetes (41). Whether these pathways contribute to increased diabetes risk in human hemochromatosis, however, is unknown. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) We previously demonstrated no change in basal or insulin-stimulated (in vivo) pAkt in skeletal muscle (18), and herein we shown that the increased hepatic glucose production occurs in the face of paradoxically increased insulin signaling in liver (Fig. 5D and E). Why insulin signaling is upregulated is not known. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Levels of the insulin-sensitizing adipokine have been shown to be elevated in Hfe-/- mice (18), but other unknown factors may also contribute, including compensation for decreased insulin levels (17) or decreased inflammatory signaling in macrophages based on their lower iron content (42). Why this increased insulin signaling does not translate to decreased levels of gluconeogenic enzymes is unclear and is under investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">13</td>
<td class="l data">alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population</td>
<td class="l data">(A) Non-targeted biochemical screening approach =&gt; non-diabetic subjects =&gt; wide spectrum of insulin sensitivity =&gt; a-hydroxybutyrate (a-HB) =&gt; biomarker =&gt; segregating =&gt; clamp-derived IR with NGT. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) a-HB segregated with dysglycaemia (IFG + IGT) independently of + in addition to IR. Associations =&gt; independent of sex, age + BMI. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) a-HB =&gt; diagnostic tool =&gt; identify IR and / or IGT earlier vs currently used clincial tests. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) a-HB =&gt; organic acid derived from a-ketobutyrate (a-KB). a-KB produced by amino acid catabolism (threonine + methionine) + glutathione anabolism (cysteine formation pathway) + metabolized =&gt; propionyl-Co-A + carbon dioxide. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) a-HB =&gt; by product =&gt; during the during the formation of a a-KB via a reaction catalyzed by lactate dehydrogenase (LDH) or a-hydroxybutyrate dehydrogenase (a-HBDH) =&gt; isoform present in the heart. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Accumulation of a-HB is postulated to occur in vivo when either: XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (1) Formation of a-HB exceeds the rate of its catabolism which leads to substrate accumulation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (2) Product inhibition of the dehydrogenase that catalyzes the conversion of a-KB to propionyl-CoA. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Methionine =&gt; (S-adenosylmethionine) SAM =&gt; methyltransferase =&gt; S-adenosylhomocysteine =&gt; homocysteine =&gt; cystathionine =&gt; homoserine =&gt; a-ketobutyrate =&gt; propionylCoA. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Threonine =&gt; a-ketobutyrate =&gt; propionylCoA. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) a-KB is also produced cystathionine to cysteine under conditions of increased oxidative stress =&gt; higher flux of cysteine into prodn of glutathione =&gt; primary anti-oxidant in cells =&gt; shift in homocysteine prodn from transmethylation of methionine =&gt; transsulfuration of homocysteine =&gt; cystathionine. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) a-HB =&gt; assoc excess glutathione demand + disrupted mitochondrial energy metabolism =&gt; derives from hepatic glutathione stress =&gt; supporting increased a-HB assoc. increased oxidative stress in IR state. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) a-HB =&gt; increased by 2 mechns: XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (1) Increase of hepatic glutathione stress =&gt; increased demand for glutathione prodn. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (2) Elevation NADH/NAD+ ratio =&gt; increased lipid oxidn. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) 1st mechn =&gt; increased a-HB formation by supplying more a-KB from increased cysteine anabolism. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Cystathionine &lt;=&gt; increased cysteine =&gt; increased Glutamate =&gt; GSH (Glutathione). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Consistent with this interpretation =&gt; statistically significant increased both a-KB + cysteine with increased IR =&gt; similar trend with a-HB. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) 2nd mechn =&gt; increased lipid oxidn =&gt; metabolic feature of IR =&gt; indexed =&gt; insulin-inhibited FFA concn. +ve assoc. =&gt; steady state FFA + plasma a-HB concns + increased NADH/NAD+ ratio favours =&gt; redn of a-KB to a-HB. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Changes in other important IR-associated metabolites =&gt; metabolic pathways =&gt; formation of a-HB + a-KB =&gt; e.g. redn glycine levels + serine upstream of a-KB formn =&gt; consistent increase gluconeogenesis =&gt; observed in IR db- / db- mice. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Redox imbalance =&gt; may contribute increased a-HB in context of IR =&gt; consistent =&gt; branched-chain (BC) alpha-keto acids eg. 3-methyl-2-oxobutyrate increase in IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Increases BC-a-keto acid =&gt; due to effect of redox imbalance =&gt; directionality of the dehydrogenases =&gt; reduce / oxidize these keto acids. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) a-HB =&gt; increase in T2D subjects + animal models of T2D + severe lactic acidosis + ketoacidosis. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Normal subjects / T2D  patients =&gt; restoration of the NADH /NAD+ redox balance by glutathione infusion therapy =&gt; increased insulin sensitivity + B-cell function. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R) Recent study =&gt; metabolic signature =&gt; accumulation of BCAA&#39;s, the glutamine / glutamate couple, several acylcarnitines + same AAA&#39;s (phenylalanine + tyrosine) =&gt; related to IR (HOMA index) =&gt; marking the metabolic consequences of excessive fat + protein intake with impairment of insulin signalling + mitochondrial overload. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Non-targeted metabolomics approach =&gt; present study =&gt; lipid molecules, BCAA&#39;s + acylcarnitines =&gt; top 30 metabolite that RF analysis associated with M-value. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Current data =&gt; narrow down the complex interactions of AA + lipid metabolism =&gt; highlight importance of a single marker, a-HB =&gt; reflects oxidative burden in context of IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Unmet need =&gt; practical clinical test =&gt; accurately measures IR =&gt; a-HB =&gt; significant biomarker =&gt; separating IR + IS subjects =&gt; using fasting plasma sample =&gt; development of diagnostic test. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) a-HB + biochemical + clinical parameters =&gt; useful =&gt; clinical indicator of subclinical abnormalities of glucose metabolism. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">14</td>
<td class="l data">Microbiota and SCFA in Lean and Overweight Healthy Subjects</td>
<td class="l data">(A) Recent reports =&gt; correlation between human gut microbiota =&gt; obesity =&gt; focus =&gt; significance of human microbiota. XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Assumption =&gt; proportional representation of the Firmicutes + Bacteroides =&gt; may play a role in the development of obesity. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) Members of both groups produce =&gt; SCFA from dietary compounds which escape digestion in the small intestine =&gt; thus supplying the host with an additional amount of energy. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Normal colonic epithelia derive 60 - 70% of their energy from SCFA, particularly butyrate. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Propionate =&gt; largely absorbed by the liver =&gt; precursor for gluconeogenesis, lipogenesis + protein synthesis. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) Acetate =&gt; enters the peripheral circulation to be metabolised by peripheral tissues =&gt; substrate for cholesterol synthesis. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Within our study group =&gt; total SCFA content =&gt; increased significantly from 84.60 mmol/l =&gt; 103.87 mmol/l =&gt; obese subjects. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Known propionate producers =&gt; belonged to the genera Bacteroides + Prevotella =&gt; joint cell numbers were more numerous in overweight (P =0.001) volunteers. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) Note =&gt; Bacteroidetes =&gt; increased in overweight + obese. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) This study consistent with previous studies =&gt; despite weight loss =&gt; no change in relevant counts of the Bacteroides spp or percentage of Firmicutes =&gt; thus the assumption that it is not the ratio of Firmicutes + Bacteroidetes that is important =&gt; but rather the amount of SCFA produced. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) When CHO intake was lowered in their study =&gt; acetate proportion increased, butyrate decreased + propionate remaind unaffected (order unchanged). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Leaner people =&gt; had a higher ratio of acetate to butyrate + propionate. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) The respective ratio =&gt; was higher, only slightly in lean volunteers of our study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Increase in the proportion of Bacteroides spp. which are the major representatives of the Bacteroidetes =&gt; from lean to obese subjects =&gt; but in contrast to earlier reports =&gt; linked an increased ratio of Firmicutes to Bacteroidetes + high amounts of SCFA to obesity. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Conversely =&gt; unable to identify any correlation of obesity with higher proportions of Firmicutes or higher concns of methanogenic Archea in obese volunteers. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Interestingly =&gt; redn of Bacteroidetes + bifidobacteria =&gt; has influence on obesity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Find a way to control for =&gt; diet, genetic background, habitation + overall fitness. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">15</td>
<td class="l data">Nutrient control of glucose homeostasis through a complex of PGC-1a and SIRT1</td>
<td class="l data">(A) SIR2 =&gt; controls lifespan in S. cerevisiae + C. elegans in repsonse to caloric restriction. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) Investigate SIRT1 =&gt; regulated by nutritional status in mice. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) SIRT1 expression in liver =&gt; NOT regulated at mRNA level in fasted mice. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) SIRT1 protein levels =&gt; induced after fasting + returned to nearly control levels upon refeeding. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Expression of PGC-1a =&gt; upregulated at the level of mRNA + protein =&gt; by fasting. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) PGC-1a + SIRT1 =&gt; increased in correlation with induction of the gluconeogenic gene PEPCK (phosphoenolpyruvate kinase). XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Lactate + pyruvate can change ratio of NAD+/NADPH + regulate SIRT1 activity =&gt; BUT were found to be fluctuating in the liver. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Pyruvate levels =&gt; increased 1.7-fold in the liver of fasted mice conversely =&gt; lactate levels decreased 2-fold. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) Measured NAD+ =&gt; a potent activator + substrate of SIRT1. Liver NAD+ levels increased 33% by fasting =&gt; returned to control levels after re-feeeding. Not detectable changes in NADH levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Data suggests =&gt; increase of SIRT1 protein levels + NAD+ concn =&gt; contributes =&gt; SIRT1 deacetylase activity in the fasted state. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) Further investigation =&gt; regulation of SIRT1 =&gt; effect of AMP or insulin =&gt; key signals of fasted response in mammals. XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) These two pathways do not affect SIRT1 protein levels in cultured hepatocytes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) By contrast =&gt; glucose + pyruvate =&gt; fluctuate in fasting =&gt; regulated SIRT1 protein levels. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Increasing concns of glucose =&gt; redn SIRT1 BUT increased concns of pyruvate =&gt; markedly increased SIRT1. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) Changes in SIRT1 protein levels =&gt; regulated =&gt; post-transcriptional level as SIRT1 mRNA =&gt; remained constant. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Pulse-chase experiment (examines cellular process over time =&gt; exposing cells =&gt; labelling compound (pulse) =&gt; + same compound in unlabelled form (chase) =&gt; analyse =&gt; whether changes =&gt; at the level of protein synthesis or degradation). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) Pulsed radiolabelled SIRT1 protein levels =&gt; did not change after chase for 6 + 12h =&gt; pyruvate treatment BUT increased SIRT1 protein in liver of fasted mice =&gt; mediated by changes in glucose +/- pyruvate. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S) Induction pattern of SIRT1 protein =&gt; correlated with expression of PGC-1a in fasting =&gt; suggesting =&gt; SIRT1 + PGC-1a interact. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T) Immunoprecipitation of endogenous SIRT1 protein from liver extracts + precipitated PGC-1a. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (U) Interaction =&gt; endogenous +/- overexpressed proteins =&gt; observed =&gt; cultured hepatocytes (293 cells). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (V) Confirm direct physical interaction =&gt; in vitro interaction assay + recombinant glutathione S-transferase (GST) PGC-1a. XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (W) PGC-1a + SIRT1 =&gt; directly interacted =&gt; suggests =&gt; PGC-1a =&gt; substrate for SIRT1 deacetylation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (X) Nicotinamide (SIRT1 inhibitor) treatment =&gt; strongly induced PGC-1a lysine acetylation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Y) Importantly =&gt; expression of SIRT1 =&gt; overcome nicotinamide-induced PGC-1a acetylation BUT SIRT1 mutant (SIRT1H355A) =&gt; lacks enzymatic activity =&gt; no effect. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Z) PGC-1a acetylation =&gt; redn fasted liver =&gt; suggesting SIRT1 activity increased in this situation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (A1) Demonstrate =&gt; SIRT1 =&gt; deacetylated PGC-1a directly =&gt; in vitro deacetylase assay =&gt; PGC-1a acetylation redn 60% =&gt; + of SIRT1 + NAD+. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B1) Map PGC-1a lysine-acetylation sites induced by nicotinamide =&gt; tandem mass spectrometry analysis =&gt; PGC-1a =&gt; acetylated at 13 lysine sites. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C1) Mutation of these 13 lysine to arginine =&gt; abolished acetylation of PGC-1a. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D1) Test the effect of PGC-1a acetylation =&gt; transcription activity =&gt; luciferase reporter assays =&gt; using transcriptor factor HNFa (TF =&gt; contains DNA binding domain DBD =&gt; attaches to DNA =&gt; promoting (activator) or blocking (repressor) =&gt; recruitment of RNA polymerase =&gt; performs transcription). XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E1) Nicotinamide treatment =&gt; redn transcriptional activity of wild-type PGC-1a / HNF4a by 24-fold. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F1) Tested several combns of PGC-1a mutants =&gt; mutant PGC-1a(R5) =&gt; 5 lysines substituted to arginine =&gt; decreased fold repression by nicotinamide to 10-fold. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G1) Two different mutants R10 + R13 =&gt; containing the R5 mutations =&gt; decreased this repression =&gt; almost control levels. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H1) Results =&gt; acetylation of PGC-1a =&gt; decreases it&#39;s ability to efficiency co-activate HNF4a. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I1) Molecular Mechns =&gt; transcriptional repression by acetylation =&gt; under investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J1) Previous studies =&gt; hormone regulation =&gt; PGC-1a expression. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K1) Gluconeogenic function of PGC-1a =&gt; may be controlled through a nutrient-sensing pathway =&gt; pyruvate + SIRT1 XXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L1) Gluconeogenic genes PEPCK + G6Pase (glucose-6-phosphatase) =&gt; induced by pyruvate treatment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M1) Effect of pyruvate =&gt; induction of G6Pase + PEPCK =&gt; reduced by specific short interfering RNA (siRNA) for PGC-1a (G6Pase redn 30% + PEPCK redn 70%) BUT not in scrambed siRNA (control) =&gt; pyruvate regulation of these genes req&#39;d PGC-1a. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N1) Use of siRNA =&gt; effect of pyruvate on PGC-1a was dependent on SIRT1. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O1) Knockdown of SIRT1 protein =&gt; largely blocked the pyruvate-induced PGC-1a increase =&gt; PEPCK + G6Pase. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P1) Pyruvate + SIRT1 effects =&gt; specific to gluconeogenic genes because PGC-1a =&gt; targeted mitochondrial genes (cytochrome-c + b-ATP synthase) NOT significantly changed. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q1) Requirement of SIRT1 =&gt; regulation of gluconeogenic gene expression by PGC-1a. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (R1) Endogenous SIRT1 + PGC-1a =&gt; recruited to chromatin promoter fragments of the PGC-1a targets PEPCK + G6Pase. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (S1) Recruitment of both proteins =&gt; increased by pyruvate treatment. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (T</td>
</tr>
<tr>
<td class="r data">16</td>
<td class="l data">Lipids and glucose in type 2 diabetes: what is the cause and effect?</td>
<td class="l data">(A) Initial perception that a disorder of glucose metabolism was the primary event in the pathogenesis of T2D, =&gt; growing appreciation =&gt; chronic increase FFA levels =&gt; early event that contributions =&gt; development of T2D. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (B) FFA&#39;s =&gt; induce IR =&gt; increase FFA levels =&gt; can be a beneficial adaptive response during starvation + pregnancy. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (C) IR =&gt; can become counterproductive  when there is excess energy intake assoc. =&gt; physical inactivity.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (D) Extra fuel =&gt; stored in visceral + subcutaneous fat depots =&gt; as fat accumulates =&gt; ongoing increase in the levels of plasma FFA&#39;s =&gt; causes IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (E) Deficit of a product of adipose tissue =&gt; adiponectin =&gt; contribute to increase IR. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (F) To counter IR + prevent hyperglycaemia =&gt; increase insulin levels. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (G) Individuals with genetic predisposition for T2D =&gt; pancreas cannot compensate for the increased secretory demands placed on it =&gt; T2D. XXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (H) Pivotal role =&gt; FFA&#39;s =&gt; IR + T2D =&gt; optimal therapeutic intervention =&gt; redn plasma FFA&#39;s. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (I) PPAR family =&gt; intimately involved in lipid metabolism. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (J) Two subtypes of these receptors =&gt; PPAR-a + PPAR-y. XXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (K) PPAR-a =&gt; increased FA oxidn. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (L) PPAR-y =&gt; redistribution of fat from visceral to subcutneous body fat + increased adiponectin. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (M) Outcome of activation of PPAR-y =&gt; redn plasma FFA concns + improved insulin sensitivity. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (N) Effects of PPAR-a on lipid metabolism =&gt; increase insulin sensitivity. XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (O) PPAR agonists =&gt; selectively activate either PPAR-a (e.g. fibrates) OR PPAR-y (eg. T2D&#39;s) =&gt; improve lipid metabolism. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (P) Dual agonism =&gt; PPAR-a/y agonists =&gt; addition benefits above + beyond those achieve through individual action on either PPAR-a or PPAR-y. XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX (Q) It may be that dual agonism with PPAR-a/Y agonists will provide additional benefits above and beyond those achieved with sole activation of either PPAR-a or PPAR-Y.</td>
</tr>
</tbody>
</table>
</div>
</div>
<br>
</div>
</body>
</html>
